Abstract: The present disclosure related to a method for screening compounds having the ability to prevent, treat or reduce malodor development on body surfaces. In particular, the method screens for compounds having the ability of preventing sweat malodor development caused by malodor causing volatile acid compounds and/or malodor causing volatile sulphur compounds. The present disclosure is based on a sensitive analytical method to determine the presence of the precursors of malodor causing volatile acid compounds and/or malodor causing volatile sulphur compounds present in sweat, which are metabolised by bacteria, such as, for example, Cornebacteria or Staphylococci to malodor causing volatile acid compounds and malodor causing volatile sulphur compounds.

Abstract: Provided are a triazine dione derivative, a preparation method therefor and an application thereof in medicine. Specifically, provided are a triazine dione derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative and a use thereof as a therapeutic agent, particularly a use in preparing a myosin inhibitor and a use in preparing a drug for treating hypertrophic cardiomyopathy (HCM) or heart diseases having pathophysiological features related to HCM.

Abstract: The present disclosure provides a service configuration method applied to an optical network unit, including: mapping initial service configuration data to at least one first managed entity at a User Network Interface side under the Management and Control Interface Protocol, and generating first service configuration information of the User Network Interface side; sending the first service configuration information to an optical line terminal for generating second service configuration information of an Access Node Interface side by the optical line terminal according to the first service configuration information; and receiving the second service configuration information sent by the optical line terminal, and performing service configuration according to the first service configuration information and the second service configuration information.

Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Abstract: Provided are an antibody against claudin 18.2 (CLDN18.2) and a use thereof in diagnosing and treating cancer of the stomach, pancreas and esophagus.

Abstract: The present application relates to a method of producing drimenol and/or drimenol derivatives by comprising contacting at least one polypeptide with farnesyl diphosphate (FPP). The method may be performed in vitro or in vivo. Also provided are amino acid sequences of polypeptides useful in the methods and nucleic acids encoding the polypeptides described. The method further provides host cells or organisms genetically modified to express the polypeptides and useful to produce drimenol and/or derivatives of drimenol.

Abstract: The present application relates to a sulfur-containing isoindoline derivative, and a preparation method therefor and medical use thereof. In particular, the present disclosure relates to a sulfur-containing isoindoline derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and use thereof as a therapeutic agent, particularly use thereof as a Cereblon modulator in the field of treatment of multiple myeloma.

Abstract: Provided are a sulfonylbenzamide derivative and a conjugate thereof, a preparation method therefor, and the use thereof. In particular, provided is a sulfonylbenzamide derivative having a structure as represented by formula (D), a conjugate thereof, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for treating cancers by means of receptor regulation. Each substituent in general formula (D) is as defined in the description.

Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.

Abstract: Disclosed are an oxa-azasipro derivative, a preparation method therefor and a pharmaceutical use thereof. In particular, disclosed are an oxa-azasipro derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use thereof as a therapeutic agent, especially the use thereof as a PI3K? inhibitor and the use thereof in the preparation of a drug for treating diseases or conditions improved by means of inhibiting PI3K?.

Abstract: A pyridine-pyrimidine derivative, a preparation method therefor and a pharmaceutical use thereof. In particular, the present disclosure relates to pyridine-pyrimidine derivative as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, especially a use thereof as an SOS1 inhibitor and a use thereof in preparation of drugs for treating diseases, conditions or disorders improved by inhibiting SOS1.

Abstract: A fused bicyclic derivative shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, particularly the use thereof as an AKT1/2/3 (AKT pan) inhibitor and the use in the preparation of a medication for treating and/or preventing tumors. Each group in general formula (I) is as defined in the description.

Abstract: A data sharing method and a device are provided. A first image is obtained by integrating a first 3D identifier and a second 3D identifier of a digital world into an image of a real world captured by a camera and performing AR rendering, the first 3D identifier is used to identify at least a building, a plant, or a mountain scenery in the real world, and the second 3D identifier is used to identify a first user in the first image. The first device displays one or a plurality of virtual objects in response to a second operation. In response to a sliding operation of which a start point of a sliding track is a first virtual object and an end point is an image of the first user, a server is requested to transmit the first virtual object to a second device.

Abstract: The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutical composition comprising said derivative, a use thereof as an estrogen receptor modulator, and a use thereof in preparing a drug for treating estrogen receptor-mediated or dependent diseases or disorders. The substituents in general formula (I) are the same as those defined in the description.

Abstract: The present disclosure relates to fused imidazole derivatives, preparation methods and medical use thereof. Specifically, the present disclosure relates to a fused imidazole derivative represented by the general formula (I), the preparation method thereof, and the pharmaceutical composition containing the same, as well as the use as a therapeutic agent, especially as GLP-1 receptor agonists, and the use thereof in the preparation of medicaments for the treatment and/or prevention of diabetes. The substituents of general formula (I) are the same as defined in the specification.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: This application provides example image display methods, media, and electronic devices . One example method includes detecting, by an electronic device that has a camera and a display, an operation of opening experience data by a user, where the experience data is stored in the electronic device and includes video data, and the video data includes multiple frames of images. A first interface is displayed in response to the operation, where the first interface includes a first image. Pose change information is determined within a preset duration, where the pose change information includes location movement information of the electronic device and pose change information of the camera. A second image including digital signage or a 3D virtual object is displayed based on pose data during collection of the first image and based on the pose change information, where the multiple frames of images include the second image.

Abstract: The disclosure provides improved vent filters useful in single-use in-line transfusion systems. In a first aspect, the disclosure provides filter comprising (i) a layer comprising a fluoropolymer membrane and (ii) a layer comprising at least two air-permeable thermoplastic polymeric layers, the air-permeable thermoplastic polymeric layers comprised of a first polymeric layer and a second polymeric layer, wherein the first polymeric layer is in bonded contact with the fluoropolymer membrane, possesses a melting point of about 95° C. to about 180° C., and wherein the second polymeric layer is in bonded contact with the first polymeric layer and has a melting point of about 220° C. to about 265° C. These filters exhibit excellent bonding strength between the various layers while preserving a considerable amount of the original fluoropolymer membrane air flux.

Abstract: The present invention relates to a claudin 18.2 (CLDN18.2) antibody and the use thereof in treating cancers, such as gastric cancer, pancreatic cancer, and esophageal cancer.

Abstract: The present application relates to an anti-CD47 single-domain antibody and a use thereof, and a method for preparing the antibody. The single-domain antibody comprises a CDR selected from the following CDRs: (1) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO:3; or (2) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.